715

(2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-A MINE

Created:	2004-08-16
Last modified:	2020-06-05

Find Related PDB Entry
3 entries where 715 is found as a standalone ligand

Find related ligands: Help
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	43
Chiral Atom Count	1
Bond Count	45
Aromatic Bond Count	11

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-A MINE
Synonyms	Sitagliptin
Systematic Name (OpenEye OEToolkits)	(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[3,4-c]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
Formula	C₁₆ H₁₅ F₆ N₅ O
Molecular Weight	407.314
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	10.04	Fc1cc(c(F)cc1F)CC(N)CC(=O)N3Cc2nnc(n2CC3)C(F)(F)F
SMILES	CACTVS	3.341	N[CH](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc3cc(F)c(F)cc3F
SMILES	OpenEye OEToolkits	1.5.0	c1c(c(cc(c1F)F)F)CC(CC(=O)N2CCn3c(nnc3C(F)(F)F)C2)N
Canonical SMILES	CACTVS	3.341	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc3cc(F)c(F)cc3F
Canonical SMILES	OpenEye OEToolkits	1.5.0	c1c(c(cc(c1F)F)F)C[C@H](CC(=O)N2CCn3c(nnc3C(F)(F)F)C2)N
InChI	InChI	1.03	InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
InChIKey	InChI	1.03	MFFMDFFZMYYVKS-SECBINFHSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB01261
Name	Sitagliptin
Groups	investigational approved
Description	Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006[L6061].
Synonyms	Sitagliptinum Sitagliptin fumarate Sitagliptin phosphate Sitagliptin hydrochloride monohydrate Sitagliptine Sitagliptina Sitagliptin malate Sitagliptin tartrate hemihydrate Sitagliptin
Brand Names	Januvia Pro-sitagliptin Malate / Metformin Hydrochloride Reddy-sitagliptin and Metformin Hydrochloride Nb-sitagliptin Mint-sitagliptin Prz-sitagliptin Teva-sitagliptin Malate Juvisync Pro-sitagliptin-metformin Nb-sitagliptin-metformin Tesavel Velmetia Sitagliptin/metformin Hydrochloride Sun Zituvio Ag-sitagliptin Sitagliptin-metformin Sitagliptin Accord Zituvimet Efficib Bio-sitagliptin PMS-sitagliptin Tartrate/metformin Auro-sitagliptin Hydrochloride and Metformin Hydrochloride Pro-sitagliptin Reddy-sitagliptin Janumet Sandoz Sitagliptin-metformin Sitagliptin Jamp Sitagliptin Ristfor Mint-sitagliptin/metformin Janumet XR Nat-sitagliptin Nra-sitagliptin Apo-sitagliptin Malate / Metformin Hydrochloride Ag-sitagliptin Hydrochloride / Metformin Sandoz Sitagliptin Riva-sitagliptin Tartrate/metformin Steglujan Sitagliptin/metformin Hydrochloride Accord Ristaben Riva Sitagliptin/metformin Brynovin Xelevia Zituvimet XR Apo-sitagliptin Prz-sitagliptin-metformin Riva Sitagliptin Ach-sitagliptin PMS-sitagliptin-metformin Apo-sitagliptin-metformin Sitagliptin Sun Sitagliptin and metformin hydrochloride Sitagliptin and Metformin Hydrochloride Sitagliptin - Metformin Teva-sitagliptin Malate / Metformin Apo-sitagliptin Malate Jamp Sitagliptin Hydrochloride / Metformin Apo-sitagliptin/metformin XR M-sitagliptin Sitagliptin Phosphate/Metformin Hydrochloride Auro-sitagliptin Pro-sitagliptin Malate PMS-sitagliptin Sandoz Sitagliptin-metformin XR Taro-sitagliptin Fumarate
Indication	Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.[L41220] It is also used in combination with [metformin] [L41215] or [ertugliflozin].[L41225]
Categories	Agents causing angioedema Alimentary Tract and Metabolism Blood Glucose Lowering Agents Cytochrome P-450 CYP2C8 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates DPP-IV Inhibitors Drugs that are Mainly Renally Excreted Drugs Used in Diabetes Enzyme Inhibitors Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Hypoglycemia-Associated Agents Incretins OAT3/SLC22A8 Substrates Oral Hypoglycemics P-glycoprotein substrates Protease Inhibitors Triazoles
ATC-Code	A10BH51 A10BD24 A10BD07 A10BD29 A10BH01 A10BD12
CAS number	486460-32-6

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
Dipeptidyl peptidase 4	MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLK...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	substrate
ATP-dependent translocase ABCB1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate
Organic anion transporter 3	MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682